A Phase 1b Open Label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics andAntitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects with Metastatic Melanoma
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
Sponsor: InxMed
Enrolling: Male and Female Patients
IRB Number: AAAS8119
U.S. Govt. ID: NCT04109456
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study consists of two treatment groups, Part 1 and Part 2. The purpose of this study is to: Part 1 - Test the safety and tolerability of the study drug IN10018, see how well the drug works on your metastatic uveal melanoma, and see how your body handles the drug. Part 2 - Test the safety and tolerability of the study drug IN10018 with cobimetinib, see how well the drug combination works on your metastatic uveal melanoma, and see how your body handles these drugs. Explore potential predictive biomarkers for IN10018 (changes that occur in your body due to IN10018) Both parts.
This study is closed
Investigator
Mariam El-Ashmawy, MD, PhD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with metastatic uveal melanoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE